People · Operator
Named in public records as an officer, director or promoter · active 2009–2023 · Biotechnology, Other, Healthtech, Media & Content
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Cellanome, Inc. | — | Biotechnology | Series D+ | $213.7M | $2.0B | 2022 |
| Vineti, Inc. | — | Biotechnology | Series C | $115.7M | $2.8B | 2016 |
| Sequenta, Inc. | — | Other | Series B | $44.9M | $332.3M | 2009 |
| Evidation Health, Inc. | — | Healthtech | Series A | $27.8M | $225.7M | 2014 |
| VitaPath Genetics, Inc. | — | Biotechnology | Series A | $13.9M | $182.1M | 2011 |
| Initiate Studios, LLC | — | Media & Content | Series A | $8.4M | $103.2M | 2020 |
| Attlee, Inc. | — | Other | Pre-Seed | $250K | $5.8M | 2009 |
Rowan Chapman at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Rowan Chapman on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Nina Kjellson | 1 | 11 |
| Emily Melton | 1 | 10 |
| Risa Stack | 1 | 9 |
| Mostafa Ronaghi | 1 | 8 |
| Michael Borrus | 1 | 7 |
| Bruce Cohen | 1 | 7 |
| Eli Casdin | 1 | 6 |
| Bill Ericson | 1 | 5 |
| David Fleshman | 1 | 5 |
| LISA SUENNEN | 1 | 5 |
| Jim Tananbaum | 1 | 4 |
| Raj Ganguly | 1 | 4 |
| Michael Pellini | 1 | 4 |
| Kazutaka Ohno | 1 | 4 |
| John Stuelpnagel | 1 | 3 |
| Jonathan Turner | 1 | 3 |
| Malek Faham | 1 | 3 |
| Thomas Willis | 1 | 3 |
| Jay Flatley | 1 | 3 |
| Mehdi Khodadad | 1 | 3 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.